GLP-1 receptor agonist

GLP-1 receptor agonists (GLP-1 RAs, also called incretin mimetics) are a class of injectable and (in one case) oral peptide medicines that bind and activate the glucagon-like peptide-1 receptor. They were originally developed for type 2 diabetes mellitus and have since become first-line for obesity, approved for cardiovascular risk reduction in obesity without diabetes, chronic kidney disease in T2DM, and MASH with stage 2–3 fibrosis.

The class has, since 2021, become the single largest growth story in outpatient medicine spending — Ozempic alone accounted for $9.2B in Medicare Part D in 2023, second only to Eliquis across all federal programs.

Mechanism

The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic β-cells, hypothalamic satiety neurons, gastric smooth muscle, cardiomyocytes, vascular endothelium, and renal tubules. Activation produces:

• β-cell: glucose-dependent insulin secretion — meaning hypoglycemia risk is low compared to sulfonylureas or insulin
• α-cell: glucagon suppression
• Stomach: delayed gastric emptying → improved postprandial glucose, prolonged satiety
• CNS: hypothalamic appetite suppression and modulation of reward circuitry — the mechanism behind both the weight loss and the widely-reported "food noise" quieting
• Cardiovascular and renal: independent of glycemia — endothelial improvement, natriuresis, weight-mediated and weight-independent blood pressure reduction, plaque stabilization

Native GLP-1 is rapidly cleaved by DPP-4 and has a plasma half-life of ~2 minutes. Every clinically useful GLP-1 RA is engineered for DPP-4 resistance, either by amino-acid substitution at position 2 (liraglutide, semaglutide), structural fusion (dulaglutide's Fc domain), or by being a non-mammalian peptide (exenatide, from Gila monster venom).

Approved agents

Generic	Brand(s)	Maker	Route	Dosing	First FDA approval	Notes
Exenatide	Byetta (BID), Bydureon (weekly)	AZ (originally Amylin)	SC	BID or 1×/wk	2005	First-in-class. Exendin-4 from Heloderma suspectum venom. US commercial market discontinued 2024.
Liraglutide	Victoza (T2DM), Saxenda (obesity)	Novo Nordisk	SC	Daily	2010 (T2DM), 2014 (obesity)	First daily GLP-1 RA. Acylated for albumin binding.
Albiglutide	Tanzeum	GSK	SC	Weekly	2014	Withdrawn 2017 (commercial).
Dulaglutide	Trulicity	Eli Lilly	SC	Weekly	2014	Fc-fusion construct.
Lixisenatide	Adlyxin (US), Lyxumia (EU)	Sanofi	SC	Daily	2016	Withdrawn US 2023.
Semaglutide	Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)	Novo Nordisk	SC or oral	Weekly SC / Daily PO	2017 SC, 2019 PO	Highest-revenue medicine on the planet (2024). Wegovy 2.4 mg also approved for CV risk reduction in obesity (SELECT) and MASH with fibrosis (ESSENCE).
Tirzepatide	Mounjaro (T2DM), Zepbound (obesity)	Eli Lilly	SC	Weekly	2022 (T2DM), 2023 (obesity)	Dual GLP-1 + GIP agonist ("twincretin"). Superior weight loss vs semaglutide in SURPASS-2 and SURMOUNT-1.

Indications

• Type 2 diabetes mellitus — first- or second-line per ADA 2025 Standards of Care, especially when ASCVD, heart failure, CKD, or obesity is co-present
• Obesity or overweight with weight-related comorbidity — BMI ≥30, or ≥27 with a weight-related condition (semaglutide 2.4 mg, tirzepatide, liraglutide 3 mg)
• Cardiovascular risk reduction in obesity without T2DM — semaglutide 2.4 mg (SELECT)
• MASH with stage 2–3 fibrosis — semaglutide (FDA 2025, based on ESSENCE)
• CKD in T2DM — semaglutide adjunctive label (FLOW)

Key trials

Trial	Agent	Population	Primary result
LEADER (2016)	Liraglutide	T2DM + high CV risk	13% ↓ MACE (NEJM 375:311)
SUSTAIN-6 (2016)	Semaglutide SC	T2DM + high CV risk	26% ↓ MACE
REWIND (2019)	Dulaglutide	T2DM + CV risk or established CVD	12% ↓ MACE — first GLP-1 RA benefit shown in primary prevention
PIONEER-6 (2019)	Semaglutide PO	T2DM + high CV risk	Non-inferior to placebo (not powered for superiority)
SURPASS-2 (2021)	Tirzepatide vs semaglutide	T2DM	Tirzepatide superior on HbA1c and weight
STEP-1 (2021)	Semaglutide 2.4 mg	Obesity without T2DM	~14.9% body-weight loss at 68 wk
SURMOUNT-1 (2022)	Tirzepatide	Obesity without T2DM	Up to ~22.5% body-weight loss at 72 wk
SELECT (2023)	Semaglutide 2.4 mg	Obesity + established CVD, no T2DM	20% ↓ MACE — landmark for obesity as a CV target
STEP-HFpEF (2023)	Semaglutide	HFpEF + obesity	↑ functional capacity (KCCQ), ↓ weight
FLOW (2024)	Semaglutide	T2DM + CKD	24% ↓ kidney + CV events; stopped early for efficacy
ESSENCE (2025)	Semaglutide 2.4 mg	MASH + fibrosis	Histologic improvement; basis for FDA approval

Adverse effects

Common (≥10%, often dose-limiting):

• Nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain
• Worse during dose escalation; mostly tolerable with slow titration
• Approximately 75% of exenatide users; less with long-acting weekly agents

Serious / labeled:

• Pancreatitis — labeled warning. Real-world data are mixed; recent large cohorts do not show a clear increase, and some show decreased acute pancreatitis incidence.
• Gallbladder disease — cholelithiasis is partly driven by rapid weight loss.
• Medullary thyroid carcinoma (MTC) / C-cell hyperplasia — boxed warning, based on rodent data (calcitonin rise). Humans show no calcitonin signal. Long-term follow-up >10 years has not been associated with increased thyroid cancer; the Bezin 2023 French case-control study found a weak signal that remains heavily debated. Contraindicated in personal or family history of MTC or MEN2.
• NAION (non-arteritic anterior ischemic optic neuropathy) — emerging signal (Hsu 2025, JAMA Ophthalmol). Small absolute risk increase.
• Aspiration risk under anesthesia — delayed gastric emptying. ASA 2024 guidance: hold weekly agents 7 days pre-op; daily agents skip the morning dose.
• Suicidality — initial EMA signal not replicated. Subsequent large studies (including JAMA Pediatrics 2024) suggest reduced suicidal ideation. FDA removed suicidality warnings January 2026.

Other monitored:

• Hypotension or syncope (volume depletion, especially with diuretics)
• Acute kidney injury (volume depletion from GI losses)
• Injection-site reactions (more with exenatide; antibody formation can reduce efficacy)

Interactions

No interactions reported yet.

+ Add an interaction

Discovery

The discovery story is one of the great late-20th-century pharmacological narratives.

Native GLP-1 was isolated in the late 1980s by Jens Juul Holst (Copenhagen) and Daniel Drucker (Toronto). Its therapeutic potential was obvious — and so was its problem: a 2-minute plasma half-life.

In 1992, John Eng, an endocrinologist at the Bronx VA Medical Center, was reading work by Pisano and Raufman noting that the venom of the Gila monster (Heloderma suspectum) caused pancreatitis in laboratory animals. Eng hypothesized that the venom must contain something incretin-like — and isolated exendin-4, a 39-amino-acid peptide 53% homologous to human GLP-1, but naturally resistant to DPP-4 cleavage. The VA declined to patent the discovery, so Eng patented it personally in 1993, licensed it to Amylin Pharmaceuticals, and the rest of the class — Byetta in 2005, then Victoza, Trulicity, Ozempic, Mounjaro — flowed from that single venom isolation.

Spending and access context

Per CMS 2023 spending data:

• Diabetes is the single largest Medicare Part D class at $59.4B in 2023
• GLP-1 RAs drove most of the +$13.8B class growth that year
• Ozempic: $9.2B Part D (#2 single medicine across all federal programs)
• Trulicity: $7.4B Part D, $2.9B Medicaid
• Mounjaro: $2.4B Part D (first full year)

These are gross figures — net spend after manufacturer rebates is materially lower, often 30–50% off list.

See also

• Type 2 diabetes mellitus
• Obesity
• GIP receptor agonist
• DPP-4 inhibitor
• SGLT2 inhibitor
• Insulin
• Metformin